Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer

Prostate

Volumn 45, Issue 1, 2000, Pages 19-35

  Candas, Bernard ^a   Cusan, Lionel ^a   Gomez, Jose Luis ^a   Diamond, Pierre ^a   Suburu, Raul E ^a   Lévesque, Jacques ^a   Brousseau, Ghislain ^a   Bélanger, Alain ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Digital rectal examination; Early diagnosis; Early treatment; Localized disease; Prostate cancer screening; Prostate specific antigen, PSA; Transrectal ultrasonography

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANADA; CANCER INCIDENCE; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; TRANSRECTAL ULTRASONOGRAPHY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOPSY; COST-BENEFIT ANALYSIS; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PALPATION; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; REPRODUCIBILITY OF RESULTS;

EID: 0033843891     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000915)45:1<19::AID-PROS3>3.0.CO;2-M     Document Type: Article

References (94)

1. Complete androgen blockade for the treatment of prostate cancer
2. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
3. Goserelin acetate and flutamide vs bilateral orchiectomy: A phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center
4. Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate-specific antigen normalization
5. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens
6. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4,128 patients using Flutamide
7. Cancer Statistics, 1999
8. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
9. Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group protocol 85-31
10. Immediate versus deferred treatment for advanced prostatic cancer Initial results of the Medical Research Council trial
11. Prostate cancer: A disease controlled by androgens
12. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
13. Evaluation of the digital rectal examination as a screening test for prostate cancer
14. Serum prostatic specific antigen (PSA) as prescreening test for prostate cancer
15. Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer
16. Optimized strategy for detection of early stage, curable prostate cancer: Role of prescreening with prostatic-specific antigen
17. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen
18. The national survey of prostate cancer in the United States by the American College of Surgeons
19. Trends in patterns of care for prostatic cancer, 1974-1983: Results of surveys by the American College of Surgeons
20. Ethics of a prostate cancer screening trial
21. Usine PSA to screen for prostate cancer
22. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
23. Screening for prostate cancer: An analysis of the early experience
24. New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen
25. Endocrine therapy for prostate cancer
26. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial
27. Final results of a screening campaign for prostate cancer
28. Purification of human prostate specific antigen
29. A prostate antigen in sera of prostatic cancer patients
30. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay
31. Use of human prostate-specific antigen in monitoring prostate cancer
32. Prostate specific antigen: A decade of discoverywhat we have learned and where we are going [In Process Citation]
33. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control
34. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update [published erratum appears in JAMA 1997;278(2):118]
35. Cancer statistics, 1996
36. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
37. Prostate cancer: Comparison of transrectal US and digital rectal examination for screening
38. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate
39. Transrectal ultrasonography. Early experience with use as prostate cancer detection tool
40. American Cancer Society National Prostate Cancer Detection Project: Results from multiple examinations by transrectal ultrasound, digital rectal examination and prostate-specific antigen
41. Adenocarcinoma of the prostate: Results of routine urological screening
42. Impact of routine screening for adenocarcinoma of the prostate on stage distribution
43. Nerve-sparing radical prostatectomy: Evaluation of results after 250 patients
44. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Cancer Society National Prostate Cancer Detection Project
45. Re: Serum prostate specific antigen as prescreening test for prostate cancer
46. Disease-specific survival following routine prostate cancer screening by digital rectal examination
47. Early detection of prostate cancer by routine screening
48. Early detection of prostate cancer following repeated examinations by multiple modalities: Results of the American Cancer Society National Prostate Cancer Detection Project
49. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen
50. What is the optimal strategy for early detection of prostate cancer?
51. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
52. The impact of family history on early detection of prostate cancer
53. Management of cancer of the prostate
54. Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist
55. Latent carcinoma of the prostate
56. Adenocarcinoma of the prostate in cystoprotatectomy specimens removed for bladder cancer
57. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: Incidence, histology and morphometric observations
58. The changing pattern of prostate cancer at the time of diagnosis: Characteristics of screen detected prostate cancer in a population-based screening study
59. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate
60. Patterns of progression in prostate cancer
61. Normal histology of the prostate
62. Cancer screening: Degrees of proof and practical application
63. Cost-benefit determinations in screening mammography
64. Physical examination and mammography in the diagnosis of breast disease
65. Monograph series on aging-related diseases. X. Prostate cancer
66. Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991 to 1993 [published erratum appears in J Urol 1998;160(6 Pt 1):2164]
67. The dilemma of prostate cancera growing human and economic burden irrespective of treatment strategies
68. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial
69. Cost-effective prostate-cancer detection: Reduction of low-field biopsies
70. Long-term survival and mortality in prostate cancer treated with noncurative intent
71. Intracrinology and cancer therapy
72. Combination of screening and preoperative endocrine therapy: The potential for an important decrease in prostate cancer mortality
73. Changing trends in U.S. prostate cancer incidence rates
74. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota
75. Cancer mortality rates fall: A turning point for the nation
76. Downward trend in prostate cancer mortality in Quebec and Canada
77. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer
78. Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma
79. Outcome for lymph node dissection negative T-1b, T-2 (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06
80. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen
81. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer
82. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
83. Should brachytherapy be considered a therapeutic option in localized prostate cancer?
84. Use of transrectal ultrasound in diagnosis, guided biopsy, staging, and screening of prostate cancer
85. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
86. Influence of benign prostatic hyperplasia, testosterone and age on serum levels of prostate-specific antigen
87. Prostate cancer mortality in patients surviving more than 10 years after diagnosis
88. Mortality in prostate cancer
89. Population-based study of long-term survival in patients with clinically localised prostate cancer
90. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: A population based registry study
91. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial